The secondary objectives are to assess the efficacy of the treatment on sub-domains of fatigue (physical, emotional and cognitive), QoL (overall and domain-specific), probable depression, functional well-being (FWB), infection frequencies, and various biomarkers (25(OH)D, HbA1c, white blood cell count, leukocyte subtype counts, serum c-reactive protein (CRP), uric acid, creatinine, triglycerides, total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol). This evidence concerns the gene CRP and infection.